pyrazolanthrone has been researched along with zearalenone in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| An, J; Guo, Y; Huang, J; Liu, H; Magyar, CE; Rettig, MB; Srivatsan, ES; Veena, MS | 1 |
1 other study(ies) available for pyrazolanthrone and zearalenone
| Article | Year |
|---|---|
Hyperactivated JNK is a therapeutic target in pVHL-deficient renal cell carcinoma.
Topics: Adaptor Proteins, Signal Transducing; Animals; Anthracenes; B-Cell CLL-Lymphoma 10 Protein; Blotting, Western; Carcinoma, Renal Cell; CARD Signaling Adaptor Proteins; Cell Line, Tumor; Enzyme Activation; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; JNK Mitogen-Activated Protein Kinases; Kidney Neoplasms; MAP Kinase Kinase 4; MAP Kinase Kinase Kinases; Mice; Mice, Nude; Phosphorylation; Proto-Oncogene Proteins c-fos; Proto-Oncogene Proteins c-jun; RNA Interference; TNF Receptor-Associated Factor 6; Von Hippel-Lindau Tumor Suppressor Protein; Xenograft Model Antitumor Assays; Zearalenone | 2013 |